Skip to content

Organon OGN Allowance for Doubtful Accounts

Allowance for Doubtful Accounts at other companies

Pfizer logo
PfizerPFE
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
Biogen logo
BiogenBIIB
PBH
Prestige Consumer HealthcarePBH
Merck & Co. logo
Merck & Co.MRK
Abbott logo
AbbottABT

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's allowance for doubtful accounts.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's allowance for doubtful accounts?
Organon (OGN) reported allowance for doubtful accounts of $14M in Q1 2026.
How has Organon's allowance for doubtful accounts changed year-over-year?
Organon's allowance for doubtful accounts increased by 16.7% year-over-year, from $12M to $14M.
What is the long-term trend for Organon's allowance for doubtful accounts?
Over 5 years (2020 to 2025), Organon's allowance for doubtful accounts has grown at a -7.8% compound annual growth rate (CAGR), from $18M to $12M.